Figure 7.
The in vivo polarizability of TAMs in the administration group was assessed by analyzing the proportion of M1/M2 subtype macrophages in the tumor tissue. (A) The proportion of M1-TAMs (CD45+F4/80+CD11b+CD86+) (**p < .01, *p < .05, vs anti-PD1 + CA-SAL). (B) The proportion of M2-TAMs (CD45+F4/80+CD11b+CD206+) (**p <.01, *p < .05, vs control group). (C) The ratio of M1/M2 TAMs (**p < .01, *p <.05, vs control group). The values are shown as mean ± SEM (n = 4–6).